Technical Analysis for APGE - Apogee Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Multiple of Ten Bullish | Other | -3.76% | |
Wide Bands | Range Expansion | -3.76% | |
Up 3 Days in a Row | Strength | -3.76% | |
Wide Bands | Range Expansion | -1.20% | |
Oversold Stochastic | Weakness | -1.20% | |
Wide Bands | Range Expansion | 2.72% | |
Oversold Stochastic | Weakness | 2.72% | |
Wide Bands | Range Expansion | 5.56% | |
Gapped Down | Weakness | 5.56% | |
Oversold Stochastic | Weakness | 5.56% |
Alert | Time |
---|---|
Down 3% | 19 minutes ago |
60 Minute Opening Range Breakdown | 27 minutes ago |
Down 2 % | about 2 hours ago |
Down 1% | about 2 hours ago |
Up 3% | about 22 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Monoclonal Antibodies Occupational Safety And Health Chronic Obstructive Pulmonary Disease Atopic Dermatitis Dermatitis Inflammatory Monoclonal Antibody Therapy Copd
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 72.29 |
52 Week Low | 14.22 |
Average Volume | 783,009 |
200-Day Moving Average | 31.41 |
50-Day Moving Average | 54.40 |
20-Day Moving Average | 52.02 |
10-Day Moving Average | 48.40 |
Average True Range | 3.74 |
RSI (14) | 45.95 |
ADX | 30.42 |
+DI | 18.06 |
-DI | 25.43 |
Chandelier Exit (Long, 3 ATRs) | 56.98 |
Chandelier Exit (Short, 3 ATRs) | 54.83 |
Upper Bollinger Bands | 60.62 |
Lower Bollinger Band | 43.41 |
Percent B (%b) | 0.4 |
BandWidth | 33.09 |
MACD Line | -2.49 |
MACD Signal Line | -2.08 |
MACD Histogram | -0.4136 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 54.61 | ||||
Resistance 3 (R3) | 54.36 | 52.69 | 53.89 | ||
Resistance 2 (R2) | 52.69 | 51.59 | 52.81 | 53.65 | |
Resistance 1 (R1) | 51.49 | 50.91 | 52.09 | 51.74 | 53.41 |
Pivot Point | 49.82 | 49.82 | 50.12 | 49.94 | 49.82 |
Support 1 (S1) | 48.62 | 48.72 | 49.22 | 48.87 | 47.19 |
Support 2 (S2) | 46.95 | 48.04 | 47.07 | 46.95 | |
Support 3 (S3) | 45.75 | 46.95 | 46.71 | ||
Support 4 (S4) | 46.00 |